Centre Hospitalier Universitaire de Liège (CHU Liège)

Hospital


Location: Liège, Belgium (BE) BE

ISNI: 0000000086076858

ROR: https://ror.org/044s61914

Show on Map:


close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrant (2023) Neven P, Fasching P, Chia S, Jerusalem G, De Laurentiis M, Im SA, Petrakova K, et al. Journal article Perspectives on the Risk-Stratified Treatment of Multiple Myeloma (2022) Davies FE, Pawlyn C, Usmani SZ, San-Miguel JF, Einsele H, Boyle EM, Corre J, et al. Journal article Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis (2022) Peyrin-Biroulet L, Arkkila P, Armuzzi A, Danese S, Guardiola J, Jahnsen J, Lees C, et al. Journal article, Review article Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study (2022) Girard N, Bar J, Garrido P, Garassino MC, McDonald F, Mornex F, Filippi AR, et al. Journal article CORE-IBD: A Multidisciplinary International Consensus Initiative to Develop a Core Outcome Set for Randomized Controlled Trials in Inflammatory Bowel Disease (2022) Ma C, Hanzel J, Panaccione R, Sandborn WJ, D'Haens GR, Ahuja V, Atreya R, et al. Journal article A comparative efficacy and safety analysis of subcutaneous infliximab and vedolizumab in patients with Crohn's Disease and Ulcerative Colitis (2022) Peyrin-Biroulet L, Arkkila P, Armuzzi A, Atreya R, Danese S, Ferrante M, Guardiola J, et al. Conference contribution Complicated Clinical Course in Incipient Gigantism Due to Treatment-resistant Aryl Hydrocarbon Receptor–Interacting Protein–mutated Pediatric Somatotropinoma (2022) van Santen SS, Daly AF, Buchfelder M, Coras R, Zhao Y, Beckers A, van der Lely AJ, et al. Journal article Quality-Adjusted Survival with Ribociclib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Postmenopausal Women with HR±HER2− Advanced Breast Cancer in the MONALEESA-3 Trial (2022) Jerusalem G, Delea TE, Martin M, De Laurentiis M, Nusch A, Beck JT, Chan A, et al. Journal article COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network (2021) Ludwig H, Sonneveld P, Facon T, San-Miguel J, Avet-Loiseau H, Mohty M, Mateos MV, et al. Journal article, Review article Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage (2021) Fernandez De Larrea C, Kyle R, Rosinol L, Paiva B, Engelhardt M, Usmani S, Caers J, et al. Journal article